On March 1, 2022, Mansfield Bio-Incubator’s new 15,000 sqft space welcomed the first two new member companies.
Turtle Health is a women-led, Boston-based start up building a clinical platform to care for women and couples in the home. The company is working on a suite of devices, diagnostics, and technology that allow doctors to confidently care for patients via telemedicine, including remote pelvic ultrasound.
The woman-led founding team is bring a depth of healthcare experience – including previous leadership roles at Sanofi, Pfizer, Evolent, McKinsey, and Blue Cross Blue Shield – as well as a passion for patient care.
Turtle Health’s team has run three successful pivotal trials that generated a number of publications, most recently a paper in Obstetrics & Gynecology (‘the Green Journal’) comparing the performance of its ultrasound device to existing in-clinic imaging. Turtle Health is hiring a Warehouse & Laboratory Operations Manager. For more information, please click here.
Beyond Biotech provides rAAV-related services and products to biological and medical researchers in the universities and biopharmaceutical companies. Our service includes rAAV vector construction/quality control, shRNA and artificial miRNA design/construction/assay, rAAV packaging, and cell-based assay for gene therapy researches.
Traditional methods of rAAV particle manufacture are time and labor-consuming process with challenge of techniques and expensive equipment. Recent rise of investments in rAAV drug development and commercialization urges plenty of researches and pre-clinical trials to use rAAV as gene delivery vehicle, which requires large quantity and high purity rAAV particles. Beyond Biotech are dedicated to employ novel and standardized protocols to produce rAAV with helper-free system in HEK293 cells, which can decrease turn-around time and the cost of rAAV manufacture.
Since the high technical procedures of rAAV design/production/quality control requires extensive cost and time for rAAV platform development, we are dedicated to develop ready-to-use rAAV packaging kits with step-by-step protocols to produce high-purity rAAV particles, which would benefit junior faculties and scientists in scientific community who work in the gene therapy field with limited funding and technical resources.
Currently, Beyond Biotech are in the early phase of R&D, in order to scale-up our manufacture, we are actively looking for funding, collaboration and investment. Please find the detailed information in our website, www.biotechbeyond.com